Advertisement

Topics

Abengoa Yield Increases Its Credit Facility in $290 Million

20:00 EDT 19 Jul 2015 | Globe Newswire

WASHINGTON, July 20, 2015 (GLOBE NEWSWIRE) -- Abengoa Yield (NASDAQ:ABY), the sustainable total return company that owns a diversified portfolio of contracted assets in the energy and environment sectors, announced today that it has increased its existing $125 million credit facility with a revolver Tranche B for an additional amount of $290 million. Tranche B was closed with Bank of America as global coordinator and joint bookrunner, HSBC as agent and joint bookrunner and Banco Santander, Citigroup, RBC, Barclays and UBS as joint bookrunners and it will be used to finance future acquisitions and for general corporate purposes.

"This increase in our credit facility proves our solid financial position and provides us with flexibility to accomplish new acquisitions and deliver accretive growth to our shareholders," said Javier Garoz, CEO of Abengoa Yield.

About Abengoa Yield

Abengoa Yield is a total return company that owns a diversified portfolio of contracted renewable energy, power generation, electric transmission and water assets in North America, South America and certain markets in EMEA. We focus on providing a predictable and growing quarterly dividend to our shareholders (www.abengoayield.com).

CFO and COO Investor Relations
Eduard Soler Leire Perez
E-mail: ir@abengoayield.com Tel: +44 20 7098 4384
  E-mail: ir@abengoayield.com
Communication Department  
Patricia Malo de Molina  
Tel: +34 954 93 71 11  
E-mail: communication@abengoa.com  
NEXT ARTICLE

More From BioPortfolio on "Abengoa Yield Increases Its Credit Facility in $290 Million"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...